Apoe (apolipoprotein E) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Apoe (apolipoprotein E) Rattus norvegicus
Symbol: Apoe
Name: apolipoprotein E
RGD ID: 2138
Description: Enables several functions, including amyloid-beta binding activity; hydroxyapatite binding activity; and phospholipid binding activity. Involved in several processes, including cellular response to alcohol; neurogenesis; and regulation of lipid metabolic process. Located in several cellular components, including endosome; microtubule; and neuronal cell body. Is extrinsic component of external side of plasma membrane. Part of several cellular components, including discoidal high-density lipoprotein particle; low-density lipoprotein particle; and triglyceride-rich plasma lipoprotein particle. Used to study artery disease (multiple); familial hyperlipidemia (multiple); glomerulosclerosis; middle cerebral artery infarction; and steatotic liver disease (multiple). Biomarker of several diseases, including glomerulonephritis (multiple); hyperhomocysteinemia; hypertension; sciatic neuropathy; and transient cerebral ischemia. Human ortholog(s) of this gene implicated in several diseases, including Alzheimer's disease (multiple); artery disease (multiple); biliary tract cancer (multiple); eye disease (multiple); and familial hyperlipidemia (multiple). Orthologous to human APOE (apolipoprotein E); PARTICIPATES IN altered lipoprotein metabolic pathway; lipoprotein metabolic pathway; Alzheimer's disease pathway; INTERACTS WITH (+)-schisandrin B; (25R)-cholest-5-ene-3beta,26-diol; 17alpha-ethynylestradiol.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: apo-E; APOEA
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Orthologs
More Info more info ...
Allele / Splice: Apoeem8Mcwi   Apoeem7Mcwi   Apoeem9Mcwi   Apoeem1Sage   Apoeem1Ejt  
Genetic Models: SD-Apoeem1Ejt SS-Apoeem7Mcwi SS-Apoeem8Mcwi SS-Apoeem9Mcwi SD-Apoeem1Sage
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
GRCr8188,481,889 - 88,485,816 (-)NCBIGRCr8
mRatBN7.2179,353,924 - 79,357,852 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl179,353,916 - 79,357,932 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx184,748,825 - 84,752,747 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0193,300,176 - 93,304,099 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0186,503,931 - 86,507,854 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0180,612,894 - 80,616,820 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl180,612,895 - 80,617,057 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0181,878,372 - 81,882,298 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4179,003,634 - 79,006,387 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1179,081,854 - 79,083,684 (-)NCBI
Celera173,813,122 - 73,817,046 (-)NCBICelera
Cytogenetic Map1q21NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
abdominal aortic aneurysm  (ISO)
adenocarcinoma  (ISO)
age related macular degeneration 1  (ISO)
Alzheimer's disease  (IEP,ISO)
Alzheimer's disease 2  (ISO)
Alzheimer's disease 3  (ISO)
Alzheimer's disease 4  (ISO)
Alzheimer's Disease, Familial, 3, with Spastic Paraparesis and Apraxia  (ISO)
amyloidosis  (ISO)
amyotrophic lateral sclerosis  (ISO)
angle-closure glaucoma  (ISO)
anxiety disorder  (ISO)
aortic atherosclerosis  (IMP)
Apolipoprotein E, Deficiency or Defect of  (ISO)
arteriosclerosis  (ISO)
atherosclerosis  (IMP,ISO)
atopic dermatitis  (ISO)
B-Cell Chronic Lymphocytic Leukemia  (ISO)
beta thalassemia  (ISO)
bile duct cancer  (ISO)
Brain Injuries  (ISO)
breast cancer  (ISO)
Broad-Betalipoproteinemia  (ISO)
cardiovascular system disease  (ISO)
carotid artery disease  (ISO)
carotid stenosis  (ISO)
cerebral amyloid angiopathy  (ISO)
Cerebral Hemorrhage  (ISO)
cerebral infarction  (ISO)
cerebrovascular disease  (ISO)
Chemical and Drug Induced Liver Injury  (ISO)
cholelithiasis  (ISO)
cholestasis  (ISO)
Chronic Brain Injury  (ISO)
Chronic Cerebral Hypoperfusion  (IEP)
Chronic Hepatitis B  (ISO)
Chronic Hepatitis C  (ISO)
cognitive disorder  (ISO)
Cognitive Dysfunction  (ISO)
congestive heart failure  (ISO)
coronary artery disease  (IMP,ISO)
Coronary Disease  (ISO)
Coumarin Sensitivity  (ISO)
dementia  (ISO)
diabetes mellitus  (ISO)
Diabetic Nephropathies  (ISO)
diabetic retinopathy  (ISO)
dilated cardiomyopathy  (ISO)
Disease Progression  (ISO)
Dysbetalipoproteinemia due to Defect in Apolipoprotein E-d  (ISO)
Dyslipidemias  (ISO)
Emphysema  (ISO)
end stage renal disease  (ISO)
Endotoxemia  (ISO)
exfoliation syndrome  (ISO)
Experimental Autoimmune Encephalomyelitis  (IEP)
Experimental Diabetes Mellitus  (IEP)
Experimental Mammary Neoplasms  (ISO)
familial combined hyperlipidemia  (ISO)
Familial Hyperbeta- and Prebetalipoproteinemia  (ISO)
familial hypercholesterolemia  (IMP,ISO)
familial hyperlipidemia  (IDA,IMP,ISO)
fetal alcohol spectrum disorder  (ISO)
Fetal Growth Retardation  (IEP)
Fibrosis  (ISO)
Floating-Betalipoproteinemia  (ISO)
gallbladder cancer  (ISO)
Genetic Translocation  (ISO)
glaucoma  (ISO)
glomerulonephritis  (ISO)
glomerulosclerosis  (IDA,IEP)
Habitual Abortions  (ISO)
Hearing Loss  (ISO)
hepatocellular carcinoma  (ISO)
herpes simplex  (ISO)
Herpes Simplex Encephalitis  (ISO)
herpes simplex virus keratitis  (ISO)
Hypercholesterolemia  (IMP,ISO)
hyperhomocysteinemia  (IEP)
Hyperlipemia with Familial Hypercholesterolemic Xanthomatosis  (ISO)
Hyperlipoproteinemia Type II  (ISO)
hyperlipoproteinemia type III  (ISO)
hypertension  (IEP,ISO)
Hypertriglyceridemia  (IMP,ISO)
hyperuricemia  (ISO)
hypothyroidism  (IEP)
kidney failure  (ISO)
Klebsiella Infections  (ISO)
Kuhnt-Junius degeneration  (ISO)
Lewy body dementia  (ISO)
Lipoprotein Glomerulopathy  (ISO)
low tension glaucoma  (ISO)
lung carcinoma  (ISO)
Lung Neoplasms  (ISO)
macular degeneration  (ISO)
malaria  (ISO)
membranous glomerulonephritis  (IEP)
Memory Disorders  (ISO)
Mercury Poisoning  (ISO)
metabolic dysfunction-associated steatotic liver disease  (IDA)
middle cerebral artery infarction  (IDA)
multiple myeloma  (ISO)
multiple sclerosis  (ISO)
myocardial infarction  (ISO)
Myocardial Ischemia  (ISO)
Neoplasm Metastasis  (ISO)
nephrotic syndrome  (ISO)
Nerve Degeneration  (ISO)
Neurobehavioral Manifestations  (ISO)
obesity  (ISO)
open-angle glaucoma  (ISO)
pancreatic cancer  (ISO)
Parkinson's disease  (ISO)
Peripheral Nerve Injuries  (IEP,ISO)
Plaque, Atherosclerotic  (ISO)
Pregnancy Complications, Infectious  (IEP)
Presenile and Senile Dementia  (ISO)
primary cutaneous amyloidosis  (ISO)
primary open angle glaucoma  (ISO)
proteinuria  (ISO)
psoriasis  (ISO)
Puromycin Aminonucleoside Nephrosis  (IEP)
relapsing-remitting multiple sclerosis  (ISO)
retinal disease  (ISO)
schizophrenia  (IEA,ISO)
sciatic neuropathy  (IEP)
sea-blue histiocytosis  (ISO)
sensorineural hearing loss  (ISO)
Sjogren's syndrome  (ISO)
sleep apnea  (ISO)
Spinal Cord Injuries  (IEP,ISO)
Splenomegaly  (ISO)
Spontaneous Abortions  (ISO)
steatotic liver disease  (IMP,ISO)
Stroke  (ISO)
Subarachnoid Hemorrhage  (ISO)
transient cerebral ischemia  (IEP)
type 1 diabetes mellitus  (ISO)
type 2 diabetes mellitus  (ISO)
Vascular System Injuries  (IEP,ISO)
Venous Thrombosis  (ISO)
Ventricular Dysfunction, Left  (ISO)
warfarin resistance  (ISO)
warfarin sensitivity  (ISO)
Wilson disease  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-catechin  (ISO)
(+)-schisandrin B  (EXP)
(25R)-cholest-5-ene-3beta,26-diol  (EXP)
(S)-nicotine  (ISO)
1,1-dichloroethene  (ISO)
11-dehydro-thromboxane B2  (ISO)
17alpha-ethynylestradiol  (EXP,ISO)
17beta-estradiol  (ISO)
17beta-hydroxy-5alpha-androstan-3-one  (ISO)
2,2',5,5'-tetrachlorobiphenyl  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,3,7,8-Tetrachlorodibenzofuran  (EXP)
2-amino-2-deoxy-D-galactopyranose  (EXP)
2-amino-2-deoxy-D-glucopyranose  (ISO)
2-arachidonoylglycerol  (ISO)
2-butoxyethanol  (ISO)
2-methyl-6-(phenylethynyl)pyridine  (ISO)
26-hydroxycholesterol  (EXP)
3',5'-cyclic GMP  (ISO)
3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine  (EXP,ISO)
3,3',4,4',5-pentachlorobiphenyl  (EXP,ISO)
3,3',5-triiodo-L-thyronine  (EXP)
3,4-methylenedioxymethamphetamine  (EXP)
3-chloropropane-1,2-diol  (EXP)
3-Nitrobenzanthrone  (ISO)
3H-1,2-dithiole-3-thione  (EXP)
4,4'-sulfonyldiphenol  (EXP,ISO)
4-hydroxy-TEMPO  (ISO)
5-aza-2'-deoxycytidine  (EXP)
6-oxoprostaglandin F1alpha  (ISO)
6-propyl-2-thiouracil  (EXP)
7,12-dimethyltetraphene  (ISO)
8-epi-prostaglandin F2alpha  (ISO)
acenocoumarol  (ISO)
acetamide  (EXP)
acetylcholine  (ISO)
acetylsalicylic acid  (ISO)
acrolein  (ISO)
aflatoxin B1  (ISO)
aldehydo-D-glucosamine  (ISO)
aldehydo-D-glucose  (ISO)
all-trans-retinoic acid  (ISO)
amiodarone  (EXP)
amitrole  (EXP)
ammonium chloride  (EXP)
amphibole asbestos  (EXP)
arachidonic acid  (ISO)
aristolochic acid A  (ISO)
Aroclor 1254  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
aspartame  (ISO)
atorvastatin calcium  (ISO)
benzo[a]pyrene  (ISO)
beta-D-glucosamine  (ISO)
bezafibrate  (EXP,ISO)
bifenthrin  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
Bisphenol B  (ISO)
bisphenol F  (EXP,ISO)
BQ 123  (ISO)
Brodifacoum  (EXP)
cadmium atom  (EXP,ISO)
cadmium dichloride  (EXP,ISO)
caffeine  (ISO)
Calcimycin  (ISO)
calcium atom  (EXP,ISO)
calcium(0)  (EXP,ISO)
capsaicin  (ISO)
captan  (ISO)
carbon nanotube  (ISO)
carnosic acid  (ISO)
cerium trichloride  (ISO)
cetirizine  (ISO)
cetrorelix  (ISO)
chlordecone  (ISO)
chloropicrin  (ISO)
chloroquine  (EXP)
chlorpyrifos  (ISO)
cholesterol  (EXP,ISO)
cisplatin  (ISO)
clofibrate  (ISO)
clofibric acid  (EXP)
clotrimazole  (EXP)
cobalt atom  (ISO)
copper atom  (EXP,ISO)
copper(0)  (EXP,ISO)
copper(II) sulfate  (ISO)
cordycepin  (ISO)
corosolic acid  (ISO)
curcumin  (ISO)
cyclophosphamide  (ISO)
cyclosporin A  (ISO)
cypermethrin  (EXP,ISO)
D-glucose  (ISO)
Deoxycorticosterone acetate  (EXP)
desogestrel  (ISO)
dexamethasone  (ISO)
dextran sulfate  (ISO)
diarsenic trioxide  (ISO)
diazinon  (EXP)
dibutyl phthalate  (EXP)
diethylstilbestrol  (EXP,ISO)
dimethylarsinic acid  (ISO)
dimethylarsinous acid  (ISO)
dipyridamole  (ISO)
diquat  (ISO)
diuron  (EXP)
dorsomorphin  (ISO)
doxorubicin  (EXP,ISO)
elemental selenium  (ISO)
enalapril  (ISO)
endosulfan  (EXP)
entinostat  (ISO)
epoxiconazole  (EXP)
ethanol  (EXP,ISO)
ethanolamine  (EXP)
felodipine  (ISO)
fenvalerate  (EXP)
Fexofenadine hydrochloride  (ISO)
flusilazole  (ISO)
flutamide  (EXP)
fluvastatin  (ISO)
folic acid  (ISO)
folpet  (ISO)
fructose  (ISO)
furan  (EXP)
Ganoderic acid A  (ISO)
gemfibrozil  (EXP)
genistein  (ISO)
gentamycin  (EXP)
gingerol  (ISO)
ginkgolide B  (ISO)
glucose  (ISO)
glutathione  (ISO)
glycidol  (EXP)
glyphosate  (ISO)
GW 3965  (EXP,ISO)
GW 4064  (ISO)
GW 7647  (ISO)
hexadecanoic acid  (ISO)
high-density lipoprotein cholesterol  (ISO)
hydrazine  (EXP)
hydrogen peroxide  (EXP)
hydroquinone  (EXP)
indometacin  (ISO)
iron atom  (ISO)
iron dichloride  (ISO)
iron(0)  (ISO)
isotretinoin  (ISO)
ivabradine  (ISO)
ivermectin  (ISO)
kaempferol  (ISO)
kainic acid  (ISO)
ketamine  (EXP,ISO)
ketoconazole  (EXP)
kuwanone G  (ISO)
L-ascorbic acid  (EXP)
lansoprazole  (ISO)
lead diacetate  (EXP,ISO)
lead(0)  (ISO)
Licochalcone B  (ISO)
lipopolysaccharide  (ISO)
lovastatin  (ISO)
mechlorethamine  (EXP)
menadione  (ISO)
mercury atom  (ISO)
mercury(0)  (ISO)
methimazole  (EXP)
methyl beta-cyclodextrin  (ISO)
methylmercury chloride  (ISO)
microcystin-LR  (ISO)
mono(2-ethylhexyl) phthalate  (EXP)
monosodium L-glutamate  (EXP,ISO)
morphine  (EXP)
Morroniside  (ISO)
myricitrin  (ISO)
N,N-diethyl-m-toluamide  (EXP)
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide  (ISO)
N-acetyl-L-cysteine  (EXP)
N-Acetyl-S-(1,2-dichlorovinyl)-cysteine  (ISO)
N-methyl-4-phenylpyridinium  (ISO)
N-nitrosodiethylamine  (EXP)
N-tosyl-L-phenylalanyl chloromethyl ketone  (ISO)
nickel atom  (ISO)
nickel sulfate  (ISO)
nicotine  (ISO)
nimesulide  (ISO)
nitric oxide  (ISO)
nitrofen  (EXP)
NONOate(1-)  (ISO)
notoginsenoside R1  (ISO)
obeticholic acid  (ISO)
ochratoxin A  (EXP)
oleic acid  (ISO)
oxaliplatin  (EXP)
ozone  (ISO)
palbociclib  (ISO)
paracetamol  (EXP,ISO)
paricalcitol  (ISO)
pentanal  (ISO)
perfluorohexanesulfonic acid  (ISO)
perfluorononanoic acid  (EXP)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (ISO)
permethrin  (EXP)
Phenelzine  (ISO)
phenobarbital  (EXP)
phenylephrine  (ISO)
phenytoin  (ISO)
phosphorus atom  (ISO)
phosphorus(.)  (ISO)
phytosterols  (ISO)
pirinixic acid  (EXP)
potassium chloride  (EXP)
probucol  (ISO)
propamocarb  (ISO)
propanal  (ISO)
Pyridostigmine bromide  (EXP)
quercetin  (ISO)
raloxifene  (ISO)
resveratrol  (EXP,ISO)
retinyl acetate  (ISO)
rotenone  (ISO)
sarin  (ISO)
SB 431542  (ISO)
selenium atom  (ISO)
sevoflurane  (ISO)
simvastatin  (EXP,ISO)
sodium arsenite  (EXP,ISO)
sodium dichromate  (EXP)
sodium fluoride  (ISO)
streptozocin  (EXP,ISO)
sulfadimethoxine  (EXP)
sunitinib  (ISO)
superoxide  (ISO)
T-2 toxin  (EXP)
tamoxifen  (ISO)
taurocholic acid  (EXP)
tert-butyl hydroperoxide  (EXP,ISO)
testosterone enanthate  (ISO)
tetrachloromethane  (EXP)
theaflavin  (ISO)
thioacetamide  (EXP)
titanium dioxide  (ISO)
tolcapone  (EXP)
topotecan  (EXP)
tributylstannane  (EXP)
trichloroethene  (EXP)
Trihexyphenidyl  (ISO)
trimellitic anhydride  (ISO)
triolein  (EXP)
triphenyl phosphate  (ISO)
triptonide  (ISO)
troglitazone  (ISO)
Tropicamide  (ISO)
trovafloxacin  (ISO)
Tungsten carbide  (ISO)
valproic acid  (EXP,ISO)
valsartan  (ISO)
vanadyl sulfate  (EXP)
varenicline  (ISO)
vitamin E  (ISO)
vitamin K  (ISO)
vitexin  (ISO)
warfarin  (ISO)
zearalenone  (ISO)
zinc atom  (ISO)
zinc sulfate  (ISO)
zinc(0)  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
acylglycerol homeostasis  (IBA)
AMPA glutamate receptor clustering  (IEA,ISO)
amyloid precursor protein metabolic process  (IEA,ISO)
artery morphogenesis  (ISO)
axon regeneration  (ISO)
cellular oxidant detoxification  (IEA)
cellular response to cholesterol  (IEP)
cellular response to ethanol  (IEP)
cellular response to growth factor stimulus  (IEP)
cellular response to interleukin-1  (IEP)
cholesterol catabolic process  (ISO)
cholesterol efflux  (IBA,IEA,ISO,ISS)
cholesterol homeostasis  (IEA,ISO)
cholesterol metabolic process  (IBA,IEA,ISO)
chylomicron remnant clearance  (IEA,ISO,ISS)
circulatory system development  (ISO)
fatty acid homeostasis  (IEA,ISO)
G protein-coupled receptor signaling pathway  (IEA,ISO)
gene expression  (ISO)
high-density lipoprotein particle assembly  (IEA,ISO,ISS)
high-density lipoprotein particle clearance  (IEA,ISO)
high-density lipoprotein particle remodeling  (IEA,ISO)
intermediate-density lipoprotein particle clearance  (IEA,ISO,ISS)
intracellular calcium ion homeostasis  (ISO)
lipid homeostasis  (ISO)
lipid metabolic process  (ISO)
lipid transport  (IDA,IEA)
lipid transport involved in lipid storage  (ISO)
lipoprotein biosynthetic process  (IEA,ISO,ISS)
lipoprotein catabolic process  (ISO)
lipoprotein metabolic process  (IDA,IEA,ISO)
locomotory exploration behavior  (IEA,ISO)
long-chain fatty acid transport  (IEA,ISO)
long-term memory  (IEA,ISO)
low-density lipoprotein particle remodeling  (ISO)
maintenance of location in cell  (ISO)
melanosome organization  (IEA,ISO,ISS)
negative regulation of amyloid fibril formation  (ISO,ISS)
negative regulation of amyloid-beta formation  (IEA,ISO)
negative regulation of blood coagulation  (ISO)
negative regulation of blood vessel endothelial cell migration  (IEA,ISO)
negative regulation of canonical Wnt signaling pathway  (IEA,ISO)
negative regulation of cholesterol biosynthetic process  (IDA,IEA,ISO)
negative regulation of cholesterol efflux  (ISO)
negative regulation of dendritic spine development  (ISO)
negative regulation of dendritic spine maintenance  (ISO)
negative regulation of endothelial cell migration  (ISO)
negative regulation of endothelial cell proliferation  (IEA,ISO)
negative regulation of gene expression  (ISO)
negative regulation of inflammatory response  (ISO)
negative regulation of lipid biosynthetic process  (ISO)
negative regulation of lipid transport across blood-brain barrier  (ISO)
negative regulation of long-term synaptic potentiation  (IEA,ISO)
negative regulation of neuron apoptotic process  (IDA)
negative regulation of neuron projection development  (IEA,ISO)
negative regulation of phospholipid efflux  (ISO)
negative regulation of platelet activation  (IEA,ISO)
negative regulation of postsynaptic membrane organization  (ISO)
negative regulation of protein metabolic process  (ISO)
negative regulation of protein secretion  (IEA,ISO)
negative regulation of smooth muscle cell proliferation  (ISO)
negative regulation of triglyceride metabolic process  (ISO)
neuron projection development  (IEA,ISO)
neuron projection regeneration  (TAS)
nitric oxide-cGMP-mediated signaling  (IEA,ISO)
NMDA glutamate receptor clustering  (IEA,ISO)
oligodendrocyte differentiation  (IEP)
peripheral nervous system axon regeneration  (IEP)
phospholipid efflux  (IBA,IEA,ISO)
positive regulation by host of viral process  (IEA,ISO)
positive regulation of amyloid-beta clearance  (ISO,ISS)
positive regulation of amyloid-beta formation  (ISO)
positive regulation of axon extension  (IDA)
positive regulation of cholesterol efflux  (IEA,ISO)
positive regulation of cholesterol metabolic process  (IEA,ISO)
positive regulation of dendritic spine development  (IEA,ISO)
positive regulation of dendritic spine maintenance  (IEA,ISO)
positive regulation of DNA-templated transcription  (IEA,ISO)
positive regulation of endocytosis  (IEA,ISO)
positive regulation of ERK1 and ERK2 cascade  (IEA,ISO)
positive regulation of lipid biosynthetic process  (IEA,ISO)
positive regulation of lipid transport across blood-brain barrier  (IEA,ISO)
positive regulation of low-density lipoprotein particle receptor catabolic process  (IEA,ISO)
positive regulation of membrane protein ectodomain proteolysis  (IEA,ISO)
positive regulation of neurofibrillary tangle assembly  (ISO)
positive regulation of neuron projection development  (IEA,ISO)
positive regulation of nitric oxide biosynthetic process  (IEA,ISO)
positive regulation of phospholipid efflux  (IEA,ISO)
positive regulation of presynaptic membrane organization  (ISO)
protein import  (IEA,ISO)
protein localization  (ISO)
receptor-mediated endocytosis  (IEA,ISO)
regulation of amyloid fibril formation  (IEA,ISO)
regulation of amyloid precursor protein catabolic process  (ISO)
regulation of amyloid-beta clearance  (IEA,ISO)
regulation of apoptotic process  (ISO)
regulation of behavioral fear response  (IEA,ISO)
regulation of Cdc42 protein signal transduction  (IEA,ISO)
regulation of cellular response to very-low-density lipoprotein particle stimulus  (IEA,ISO)
regulation of cholesterol metabolic process  (ISO)
regulation of gene expression  (ISO)
regulation of innate immune response  (ISO)
regulation of plasma lipoprotein particle levels  (ISO)
regulation of proteasomal protein catabolic process  (IEA,ISO)
regulation of protein metabolic process  (ISO)
regulation of protein-containing complex assembly  (IEA,ISO)
regulation of synapse organization  (ISO)
regulation of triglyceride metabolic process  (IDA)
response to caloric restriction  (IEA,ISO)
response to D-galactosamine  (IEP)
response to dietary excess  (ISO)
response to ethanol  (IEP)
response to insulin  (IEP)
response to oxidative stress  (ISO)
response to retinoic acid  (IEP)
response to tumor necrosis factor  (IEP)
response to zinc ion  (IEP)
reverse cholesterol transport  (IEA,ISO)
triglyceride homeostasis  (ISO)
triglyceride metabolic process  (IEA,ISO)
triglyceride-rich lipoprotein particle clearance  (ISO,ISS)
vasodilation  (ISO)
very-low-density lipoprotein particle clearance  (IEA,ISO,ISS)
very-low-density lipoprotein particle remodeling  (IEA,ISO)
virion assembly  (IEA,ISO)

Molecular Pathway Annotations     Click to see Annotation Detail View

References - curated
# Reference Title Reference Citation
1. Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. null
2. Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Alikhani N, etal., Oncogene. 2013 Feb 21;32(8):961-7. doi: 10.1038/onc.2012.113. Epub 2012 Apr 2.
3. Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. Andreotti G, etal., Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):525-34. Epub 2008 Feb 22.
4. Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex. Arold S, etal., Acta Neuropathol. 2012 Jan;123(1):39-52. Epub 2011 Oct 22.
5. Deficiency of a transcriptional regulator, inhibitor of differentiation 3, induces glomerulonephritis in apolipoprotein E-deficient mice: a model linking hyperlipidemia and renal disease. Bagavant H, etal., Am J Pathol. 2011 Aug;179(2):651-60. Epub 2011 Jun 14.
6. APOE and APOC1 genetic polymorphisms in age-associated memory impairment. Bartres-Faz D, etal., Neurogenetics. 2001 Oct;3(4):215-9.
7. The genetic association database. Becker KG, etal., Nat Genet. 2004 May;36(5):431-2.
8. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. Bellosta S, etal., J Clin Invest. 1995 Nov;96(5):2170-9.
9. Effective treatment of ocular HSK with a human apolipoprotein E mimetic peptide in a mouse eye model. Bhattacharjee PS, etal., Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4263-8. doi: 10.1167/iovs.08-2077. Epub 2008 May 30.
10. Fetal adrenal gland alterations in a rat model of adverse intrauterine environment. Bibeau K, etal., Am J Physiol Regul Integr Comp Physiol. 2010 Apr;298(4):R899-911. Epub 2009 Nov 18.
11. Effects of apolipoproteins A-IV and A-I on the uptake of phospholipid liposomes by hepatocytes. Bisgaier CL, etal., J Biol Chem. 1989 Jan 15;264(2):862-6.
12. Intestinal lipoproteins in the rat with D-(+)-galactosamine hepatitis. Black DD, etal., J Lipid Res. 1983 Aug;24(8):977-92.
13. Apolipoprotein E epsilon4 allele is associated with left ventricular systolic dysfunction. Bleumink GS, etal., Am Heart J. 2004 Apr;147(4):685-9.
14. Accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve. Identification of apolipoprotein D, apolipoprotein A-IV, apolipoprotein E, and apolipoprotein A-I. Boyles JK, etal., J Biol Chem. 1990 Oct 15;265(29):17805-15.
15. A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. Boyles JK, etal., J Clin Invest. 1989 Mar;83(3):1015-31.
16. Protective peptides that are orally active and mechanistically nonchiral. Brenneman DE, etal., J Pharmacol Exp Ther. 2004 Jun;309(3):1190-7. Epub 2004 Mar 8.
17. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. Breslow JL, etal., J Lipid Res. 1982 Nov;23(8):1224-35.
18. Chronic renal failure alters endothelial function in cerebral circulation in mice. Bugnicourt JM, etal., Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H1143-52. Epub 2011 Jun 24.
19. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Campalani E, etal., Br J Dermatol. 2006 Feb;154(2):345-52.
20. The apolipoprotein E genotype predicts postprandial hypertriglyceridemia in patients with the metabolic syndrome. Cardona F, etal., J Clin Endocrinol Metab. 2005 May;90(5):2972-5. Epub 2005 Feb 15.
21. Alterations in lipoprotein composition associated with galactosamine-induced rat liver injury. Cartwright CK, etal., J Lipid Res. 1982 Jul;23(5):667-79.
22. Microarray analysis of cultured rat hippocampal neurons treated with brain derived neurotrophic factor. Cazzin C, etal., Mol Biol Rep. 2011 Feb;38(2):983-90. Epub 2010 Jun 10.
23. Characterizations and proteome analysis of platelet-free plasma-derived microparticles in beta-thalassemia/hemoglobin E patients. Chaichompoo P, etal., J Proteomics. 2012 Dec 5;76 Spec No.:239-50. doi: 10.1016/j.jprot.2012.06.004. Epub 2012 Jun 15.
24. Influences of apolipoprotein E polymorphism on the risk for breast cancer and HER2/neu status in Taiwan. Chang NW, etal., Breast Cancer Res Treat. 2005 Apr;90(3):257-61.
25. Association between the apolipoprotein E genotypes and breast cancer patients in Taiwanese. Chang SJ, etal., Breast Cancer Res Treat. 2006 Jul;98(1):109-13. Epub 2006 Jun 5.
26. The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet. Chang XX, etal., Lipids Health Dis. 2012 Jul 4;11(1):86.
27. APOE polymorphism and angiographic coronary artery disease severity in the Women's Ischemia Syndrome Evaluation (WISE) study. Chen Q, etal., Atherosclerosis. 2003 Jul;169(1):159-67.
28. Low cholesterol in dialysis patients--causal factor for mortality or an effect of confounding? Chmielewski M, etal., Nephrol Dial Transplant. 2011 Oct;26(10):3325-31. Epub 2011 Feb 28.
29. SINGLE NUCLEOTIDE POLYMORPHISMS THAT INFLUENCE LIPID METABOLISM: Interaction with Dietary Factors. Corella D and Ordovas JM, Annu Rev Nutr. 2005;25:341-90.
30. [Comparative plasma proteomic analysis of patients with multiple myeloma treated with bortezomib-based regimens]. Cumova J, etal., Klin Onkol. 2012;25(1):17-25.
31. Concentration of intracellular hepatic apolipoprotein E in Golgi apparatus saccular distensions and endosomes. Dahan S, etal., J Cell Biol. 1994 Dec;127(6 Pt 2):1859-69.
32. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. Daugherty A, etal., J Clin Invest. 2000 Jun;105(11):1605-12.
33. Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. de Bont N, etal., Eur J Clin Invest. 2000 Sep;30(9):818-22.
34. Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis. Diaz JA, etal., J Vasc Surg. 2012 Mar;55(3):815-22. Epub 2011 Nov 25.
35. Magnesium sulfate reduces bacterial LPS-induced inflammation at the maternal-fetal interface. Dowling O, etal., Placenta. 2012 May;33(5):392-8. doi: 10.1016/j.placenta.2012.01.013. Epub 2012 Feb 16.
36. Apolipoprotein E epsilon4 allele as a genetic risk factor for left ventricular failure in homozygous beta-thalassemia. Economou-Petersen E, etal., Blood. 1998 Nov 1;92(9):3455-9.
37. Effect of polymorphisms of the MTHFR and APOE genes on susceptibility to diabetes and severity of diabetic retinopathy in Brazilian patients. Errera FI, etal., Braz J Med Biol Res. 2006 Jul;39(7):883-8.
38. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/'null' genotype. Feussner G, etal., Eur J Clin Invest. 1992 Sep;22(9):599-608.
39. Subsets of SNPs define rare genotype classes that predict ischemic heart disease. Frikke-Schmidt R, etal., Hum Genet. 2007 Feb;120(6):865-877. Epub 2006 Sep 28.
40. Age-related macular degeneration and functional promoter and coding variants of the apolipoprotein E gene. Fritsche LG, etal., Hum Mutat. 2009 Jul;30(7):1048-53. doi: 10.1002/humu.20957.
41. Apolipoprotein E is present in primary localized cutaneous amyloidosis. Furumoto H, etal., J Invest Dermatol. 1998 Sep;111(3):417-21.
42. Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Gao J, etal., Diabetes. 2007 Jan;56(1):24-33.
43. Establishment of a rat model with diet-induced coronary atherosclerosis. Gao M, etal., J Biomed Res. 2016 Oct 17;31(1):47-55. doi: 10.7555/JBR.31.20160020.
44. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
45. Apolipoprotein E genotype is associated with differential expansion rates of small abdominal aortic aneurysms. Gerdes LU, etal., Br J Surg. 2000 Jun;87(6):760-5.
46. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
47. The association of Apoprotein E polymorphisms with recurrent pregnancy loss. Goodman C, etal., Am J Reprod Immunol. 2009 Jan;61(1):34-8. doi: 10.1111/j.1600-0897.2008.00659.x.
48. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Gronborg M, etal., Mol Cell Proteomics. 2006 Jan;5(1):157-71. Epub 2005 Oct 8.
49. Ethanol induces cholesterol efflux and up-regulates ATP-binding cassette cholesterol transporters in fetal astrocytes. Guizzetti M, etal., J Biol Chem. 2007 Jun 29;282(26):18740-9. Epub 2007 May 3.
50. Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1. Hayashi H, etal., J Neurosci. 2007 Feb 21;27(8):1933-41.
51. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. Hirashiki A, etal., J Am Coll Cardiol. 2003 Oct 15;42(8):1429-37.
52. The apolipoprotein E epsilon4-allele and antihypertensive treatment are associated with increased risk of cerebral MRI white matter hyperintensities. Hogh P, etal., Acta Neurol Scand. 2007 Apr;115(4):248-53.
53. Selective alterations in the cellular distribution of apolipoprotein E immunoreactivity following transient cerebral ischaemia in the rat. Horsburgh K and Nicoll JA, Neuropathol Appl Neurobiol. 1996 Aug;22(4):342-9.
54. Proteomic identification of biomarkers of vascular injury. Huang NF, etal., Am J Transl Res. 2011 Feb;3(2):139-48. Epub 2010 Nov 21.
55. Expression of apolipoprotein E during nerve degeneration and regeneration. Ignatius MJ, etal., Proc Natl Acad Sci U S A. 1986 Feb;83(4):1125-9.
56. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Inbal A, etal., Blood. 1999 Apr 1;93(7):2186-90.
57. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. Ishigaki Y, etal., J Biol Chem. 2000 Oct 6;275(40):31269-73.
58. Apolipoprotein E modifies neurological outcome by affecting cerebral edema but not hematoma size after intracerebral hemorrhage in humans. James ML, etal., J Stroke Cerebrovasc Dis. 2009 Mar-Apr;18(2):144-9.
59. Apolipoprotein E epsilon4 allele and outcomes of traumatic spinal cord injury. Jha A, etal., J Spinal Cord Med. 2008;31(2):171-6.
60. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. Jordan BD, etal., JAMA. 1997 Jul 9;278(2):136-40.
61. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. Joven J, etal., N Engl J Med. 1990 Aug 30;323(9):579-84.
62. Is the ApoE polymorphism associated with dilated cardiomyopathy? Jurkovicova D, etal., Gen Physiol Biophys. 2006 Mar;25(1):3-10.
63. Spatiotemporal changes of apolipoprotein E immunoreactivity and apolipoprotein E mRNA expression after transient middle cerebral artery occlusion in rat brain. Kamada H, etal., J Neurosci Res 2003 Aug 15;73(4):545-56.
64. Proteome analysis of rat serum proteins adsorbed onto synthetic octacalcium phosphate crystals. Kaneko H, etal., Anal Biochem. 2011 Nov 15;418(2):276-85. Epub 2011 Jul 26.
65. Apolipoprotein E gene polymorphism in psoriasis. Karpouzis A, etal., Arch Dermatol Res. 2009 Jul;301(6):405-10. doi: 10.1007/s00403-009-0968-0. Epub 2009 Jun 5.
66. KEGG: Kyoto Encyclopedia of Genes and Genomes KEGG
67. Effect of fungal polysaccharides on the modulation of plasma proteins in streptozotocin-induced diabetic rats. Kim SW, etal., Proteomics. 2006 Oct;6(19):5291-302.
68. Glycoproteomic analysis of plasma from patients with atopic dermatitis: CD5L and ApoE as potential biomarkers. Kim WK, etal., Exp Mol Med. 2008 Dec 31;40(6):677-85.
69. Preferential interactions between ApoE-containing lipoproteins and Abeta revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift. LaDu MJ, etal., Biochim Biophys Acta. 2012 Feb;1821(2):295-302. Epub 2011 Nov 23.
70. Association of human, rat, and rabbit apolipoprotein E with beta-amyloid. LaDu MJ, etal., J Neurosci Res. 1997 Jul 1;49(1):9-18.
71. Association of apolipoprotein E polymorphisms with normal tension glaucoma in a Chinese population. Lam CY, etal., J Glaucoma. 2006 Jun;15(3):218-22.
72. Expression profiles of cholesterol metabolism-related genes are altered during development of experimental autoimmune encephalomyelitis in the rat spinal cord. Lavrnja I, etal., Sci Rep. 2017 Jun 2;7(1):2702. doi: 10.1038/s41598-017-02638-8.
73. Red mold rice promotes neuroprotective sAPPalpha secretion instead of Alzheimer's risk factors and amyloid beta expression in hyperlipidemic Abeta40-infused rats. Lee CL, etal., J Agric Food Chem. 2010 Feb 24;58(4):2230-8. doi: 10.1021/jf904027y.
74. Knockout rat models mimicking human atherosclerosis created by Cpf1-mediated gene targeting. Lee JG, etal., Sci Rep. 2019 Feb 22;9(1):2628. doi: 10.1038/s41598-019-38732-2.
75. Combined effects of EFA deficiency and tumor necrosis factor-alpha on circulating lipoproteins in rats. Levy E, etal., Lipids. 2003 Jun;38(6):595-602.
76. An apolipoprotein E-mimetic stimulates axonal regeneration and remyelination after peripheral nerve injury. Li FQ, etal., J Pharmacol Exp Ther. 2010 Jul;334(1):106-15. Epub 2010 Apr 20.
77. Glucose concentration in the dialysate does not contribute to lipid profiles in patients undergoing CAPD. Li Z and Fengxian H, Ren Fail. 2011;33(2):124-30.
78. Apolipoprotein E gene polymorphisms and retinal vascular signs: the atherosclerosis risk in communities (ARIC) study. Liew G, etal., Arch Ophthalmol. 2007 Jun;125(6):813-8.
79. Herpes simplex encephalitis: involvement of apolipoprotein E genotype. Lin WR, etal., J Neurol Neurosurg Psychiatry. 2001 Jan;70(1):117-9.
80. Apolipoprotein E expression is elevated by interleukin 1 and other interleukin 1-induced factors. Liu L, etal., J Neuroinflammation. 2011 Dec 15;8:175.
81. Insulin increases central apolipoprotein E levels as revealed by an improved technique for collection of cerebrospinal fluid from rats. Liu M, etal., J Neurosci Methods. 2012 Jul 30;209(1):106-12. Epub 2012 Jun 9.
82. Fcgamma receptor deficiency attenuates diabetic nephropathy. Lopez-Parra V, etal., J Am Soc Nephrol. 2012 Sep;23(9):1518-27. Epub 2012 Aug 2.
83. A role for LRP4 in neuronal cell viability is related to apoE-binding. Lu Y, etal., Brain Res. 2007 Oct 26;1177:19-28. Epub 2007 Aug 25.
84. Apolipoprotein E promoter polymorphisms (-491A/T and -427T/C) and Alzheimer's disease: no evidence of association in the Irish population. Lynch CA, etal., Ir J Med Sci. 2008 Mar;177(1):29-33. Epub 2007 Dec 5.
85. The apolipoprotein E gene polymorphism is associated with open angle glaucoma in the Japanese population. Mabuchi F, etal., Mol Vis. 2005 Aug 12;11:609-12.
86. Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. Malek G, etal., Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11900-5. Epub 2005 Aug 3.
87. Chronic ethanol exposure in rats affects rabs-dependent hepatic trafficking of apolipoprotein E and transferrin. Marmillot P, etal., Alcohol. 2001 Nov;25(3):195-200.
88. Meta-analysis of genome-wide gene expression differences in onset and maintenance phases of genetic hypertension. Marques FZ, etal., Hypertension. 2010 Aug;56(2):319-24. Epub 2010 Jun 28.
89. Involvement of low-density lipoprotein receptor-related protein and ABCG1 in stimulation of axonal extension by apoE-containing lipoproteins. Matsuo M, etal., Biochim Biophys Acta. 2011 Jan;1811(1):31-8. Epub 2010 Oct 30.
90. High density lipoprotein subpopulations from galactosamine-treated rats and their transformation by lecithin:cholesterol acyltransferase. Matsuura JE and Swaney JB, J Lipid Res. 1991 Apr;32(4):581-94.
91. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
92. Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Miklossy J, etal., Neurobiol Aging. 2008 Oct 23.
93. Isoform-specific effects of ApoE on HSV immediate early gene expression and establishment of latency. Miller RM and Federoff HJ, Neurobiol Aging. 2008 Jan;29(1):71-7. Epub 2006 Nov 13.
94. Genetic associations in diabetic nephropathy: a meta-analysis. Mooyaart AL, etal., Diabetologia. 2011 Mar;54(3):544-53. Epub 2010 Dec 3.
95. Apolipoprotein E genotyping in sporadic amyotrophic lateral sclerosis: evidence for a major influence on the clinical presentation and prognosis. Moulard B, etal., J Neurol Sci. 1996 Aug;139 Suppl:34-7.
96. Apolipoprotein E and lipoprotein lipase increase triglyceride-rich particle binding but decrease particle penetration in arterial wall. Mullick AE, etal., Arterioscler Thromb Vasc Biol 2002 Dec 1;22(12):2080-5.
97. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. Nakano T, etal., J Hepatol. 2011 Aug;55(2):415-25. Epub 2010 Dec 22.
98. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
99. Liver X receptors regulate cholesterol homeostasis in oligodendrocytes. Nelissen K, etal., J Neurosci Res. 2012 Jan;90(1):60-71. doi: 10.1002/jnr.22743. Epub 2011 Oct 3.
100. FGF-1-induced reactions for biogenesis of apoE-HDL are mediated by src in rat astrocytes. Nishida T, etal., J Biochem. 2009 Dec;146(6):881-6. Epub 2009 Aug 27.
101. Apolipoprotein E alleles and sensorineural hearing loss. O'Grady G, etal., Int J Audiol. 2007 Apr;46(4):183-6.
102. Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy. Oikawa S, etal., J Am Soc Nephrol. 1997 May;8(5):820-3.
103. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
104. Combined germline variations of thrombophilic genes promote genesis of lung cancer. Ozen F, etal., Asian Pac J Cancer Prev. 2013;14(9):5449-54.
105. Regulation of apolipoprotein A-1 and E gene expression in liver and intestine of nephrotic and pair-fed rats. Panduro A, etal., Nephron. 1993;65(1):100-7.
106. The apolipoprotein E epsilon4 allele is unlikely to be a major risk factor of age-related macular degeneration in Chinese. Pang CP, etal., Ophthalmologica. 2000;214(4):289-91.
107. Apolipoprotein E polymorphism influences lipid phenotypes in Chinese families with familial combined hyperlipidemia. Pei WD, etal., Circ J. 2006 Dec;70(12):1606-10.
108. Presence of apolipoprotein E epsilon4 allele predisposes to early onset of primary Sjogren's syndrome. Pertovaara M, etal., Rheumatology (Oxford). 2004 Dec;43(12):1484-7. Epub 2004 Aug 24.
109. Angiotensin II Infusion Does Not Cause Abdominal Aortic Aneurysms in Apolipoprotein E-Deficient Rats. Phillips EH, etal., J Vasc Res. 2018;55(1):1-12. doi: 10.1159/000484086. Epub 2017 Nov 23.
110. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
111. Early hypercholesterolemia contributes to vasomotor dysfunction and injury associated atherogenesis that can be inhibited by nitric oxide. Raman KG, etal., J Vasc Surg. 2011 Mar;53(3):754-63. Epub 2010 Dec 15.
112. Postprandial triglyceride levels in familial combined hyperlipidemia. The role of apolipoprotein E and lipoprotein lipase polymorphisms. Reiber I, etal., J Nutr Biochem. 2003 Jul;14(7):394-400.
113. Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats In vivo. Rensen PC, etal., J Clin Invest. 1997 May 15;99(10):2438-45.
114. Apolipoprotein E promoter polymorphisms do not have a major influence on the risk of developing primary open angle glaucoma. Ressiniotis T, etal., Mol Vis. 2004 Oct 28;10:805-7.
115. GOA pipeline RGD automated data pipeline
116. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
117. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
118. Combined serum and tissue proteomic study applied to a c-Myc transgenic mouse model of hepatocellular carcinoma identified novel disease regulated proteins suitable for diagnosis and therapeutic intervention strategies. Ritorto MS and Borlak J, J Proteome Res. 2011 Jul 1;10(7):3012-30. Epub 2011 Jun 6.
119. Epistatic Interactions between apolipoprotein E and hemoglobin S Genes in regulation of malaria parasitemia. Rougeron V, etal., PLoS One. 2013 Oct 8;8(10):e76924. doi: 10.1371/journal.pone.0076924. eCollection 2013.
120. Enriched environment reduces apolipoprotein E (ApoE) in reactive astrocytes and attenuates inflammation of the peri-infarct tissue after experimental stroke. Ruscher K, etal., J Cereb Blood Flow Metab. 2009 Nov;29(11):1796-805. Epub 2009 Jul 22.
121. The effect of old age on apolipoprotein E and its receptors in rat liver. Sabaretnam T, etal., Age (Dordr). 2009 Oct 7.
122. Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease. Scacchi R, etal., Neurosci Lett. 1999 Jan 4;259(1):33-6.
123. A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy. Schmidt S, etal., Ophthalmic Genet. 2002 Dec;23(4):209-23.
124. Robust association of the APOE epsilon4 allele with premature myocardial infarction especially in patients without hypercholesterolaemia: the Aachen study. Schmitz F, etal., Eur J Clin Invest. 2007 Feb;37(2):106-8.
125. Apolipoprotein E gene polymorphism is not a strong risk factor for diabetic nephropathy and retinopathy in Type I diabetes: case-control study. Shcherbak NS BMC Med Genet. 2001;2:8. Epub 2001 Jul 24.
126. Hepatic and renal expression of rat apolipoprotein E under control of the metallothionein promoter in transgenic mice. Shimano H, etal., Biochim Biophys Acta. 1991 Aug 27;1090(1):91-4.
127. Intermediate phenotypes identify divergent pathways to Alzheimer's disease. Shulman JM, etal., PLoS One. 2010 Jun 21;5(6):e11244. doi: 10.1371/journal.pone.0011244.
128. A discovery-phase urine proteomics investigation in type 1 diabetes. Soggiu A, etal., Acta Diabetol. 2012 Jun 8.
129. The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration. Souied EH, etal., Am J Ophthalmol. 1998 Mar;125(3):353-9.
130. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Strausberg RL, etal., Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903. Epub 2002 Dec 11.
131. The usefulness of measuring body fat deposition for detecting obesity and atherogenesity in Japanese school children. Takahashi H, etal., Acta Paediatr Jpn. 1996 Dec;38(6):634-9.
132. Tentative Sequence Identification Numbers Tentative Sequence Data IDs. TIGR Gene Index, Rat Data
133. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Utermann G, etal., Nature. 1977 Oct 13;269(5629):604-7.
134. Apolipoprotein E gene promoter (-219G/T) polymorphism is associated with premature coronary heart disease. Viitanen L, etal., J Mol Med. 2001 Dec;79(12):732-7. Epub 2001 Jul 25.
135. Chronic Cerebral Hypoperfusion Induced Synaptic Proteome Changes in the rat Cerebral Cortex. Völgyi K, etal., Mol Neurobiol. 2018 May;55(5):4253-4266. doi: 10.1007/s12035-017-0641-0. Epub 2017 Jun 15.
136. Proteinuria decreases tissue lipoprotein receptor levels resulting in altered lipoprotein structure and increasing lipid levels. Wang L, etal., Kidney Int. 2012 Jul 11. doi: 10.1038/ki.2012.244.
137. Olfactory identification and apolipoprotein E epsilon 4 allele in mild cognitive impairment. Wang QS, etal., Brain Res. 2002 Sep 27;951(1):77-81.
138. Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia. Weinberg JB, etal., Leukemia. 2008 Dec;22(12):2184-92. doi: 10.1038/leu.2008.241. Epub 2008 Sep 11.
139. Effects of triiodothyronine and propylthiouracil on plasma lipoproteins in male rats. Wilcox HG, etal., J Lipid Res. 1982 Nov;23(8):1159-66.
140. Apolipoprotein E and LRP1 Increase Early in Parkinson's Disease Pathogenesis. Wilhelmus MM, etal., Am J Pathol. 2011 Nov;179(5):2152-6. doi: 10.1016/j.ajpath.2011.07.021. Epub 2011 Sep 9.
141. Cell surface "blanket" of apolipoprotein E on rat adrenocortical cells. Williams DL, etal., J Lipid Res. 1995 Apr;36(4):745-58.
142. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Wozniak MA, etal., Hepatology. 2002 Aug;36(2):456-63.
143. Role of apolipoprotein E in lipoprotein metabolism and in the process of atherosclerosis. Yamada N, etal., J Atheroscler Thromb. 1995;2 Suppl 1:S29-33.
144. Genetic risk for coronary artery disease in individuals with or without type 2 diabetes. Yamada Y, etal., Mol Genet Metab. 2004 Apr;81(4):282-90.
145. Genetic risk for atherothrombotic cerebral infarction in individuals stratified by sex or conventional risk factors for atherosclerosis. Yamaguchi S, etal., Int J Mol Med. 2006 Nov;18(5):871-83.
146. Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. Yan L, etal., J Proteome Res. 2009 Jan;8(1):142-8.
147. Effects of apolipoprotein E genotypes on the development of exfoliation syndrome. Yilmaz A, etal., Exp Eye Res. 2005 Jun;80(6):871-5.
148. Investigation of the relationship between apolipoprotein E gene polymorphisms and hepatitis B virus infection in northern China. Yin Z, etal., Clin Chem Lab Med. 2010 Dec;48(12):1803-7. doi: 10.1515/CCLM.2010.354. Epub 2010 Oct 20.
149. [A study on the association of apolipoprotein E genotypes with primary open-angle glaucoma and primary angle-closure glaucoma in northeast of China]. Yuan HP, etal., Zhonghua Yan Ke Za Zhi. 2007 May;43(5):416-20.
150. Endogenous adipocyte apolipoprotein E is colocalized with caveolin at the adipocyte plasma membrane. Yue L and Mazzone T, J Lipid Res. 2011 Mar;52(3):489-98. Epub 2010 Dec 16.
151. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Zhang SH, etal., Science 1992 Oct 16;258(5081):468-71.
152. Hyperlipidemia induces typical atherosclerosis development in Ldlr and Apoe deficient rats. Zhao Y, etal., Atherosclerosis. 2018 Apr;271:26-35. doi: 10.1016/j.atherosclerosis.2018.02.015. Epub 2018 Feb 12.
153. Identification of differentially expressed proteins in rats with spinal cord injury during the transitional phase using an iTRAQ-based quantitative analysis. Zhou H, etal., Gene. 2018 Jul 20. pii: S0378-1119(18)30820-5. doi: 10.1016/j.gene.2018.07.050.
154. Less gelatinases is associated with apolipoprotein E accumulation in glomerulosclerosis rats. Zhou TB, etal., Histol Histopathol. 2012 Feb;27(2):249-56.
155. All-trans retinoic acid can regulate the expressions of gelatinases and apolipoprotein E in glomerulosclerosis rats. Zhou TB, etal., Vascul Pharmacol. 2011 Nov-Dec;55(5-6):169-77. Epub 2011 Sep 2.
Additional References at PubMed
PMID:210174   PMID:210175   PMID:1384047   PMID:1423598   PMID:1530612   PMID:1911868   PMID:1917954   PMID:2280190   PMID:2745454   PMID:2762297   PMID:3020048   PMID:3771793  
PMID:3797247   PMID:4066713   PMID:6190813   PMID:7566652   PMID:7592957   PMID:7635945   PMID:7683668   PMID:7766086   PMID:7798939   PMID:8071364   PMID:8089103   PMID:8127890  
PMID:8185566   PMID:8245722   PMID:8300609   PMID:8340399   PMID:8647961   PMID:8773783   PMID:8939961   PMID:8995232   PMID:9003062   PMID:9186920   PMID:9240444   PMID:9300780  
PMID:9325076   PMID:9488694   PMID:9649566   PMID:9685360   PMID:9788969   PMID:9826706   PMID:11120757   PMID:11162594   PMID:11305869   PMID:11551841   PMID:11553788   PMID:12042316  
PMID:12401887   PMID:12870266   PMID:12950167   PMID:13130124   PMID:14595002   PMID:14741101   PMID:14754908   PMID:15269218   PMID:15489334   PMID:15654758   PMID:15866734   PMID:15950758  
PMID:16230502   PMID:16273551   PMID:16376010   PMID:16443932   PMID:16497717   PMID:16502470   PMID:16524875   PMID:16802110   PMID:16805831   PMID:16935699   PMID:17012232   PMID:17126342  
PMID:17154273   PMID:17305370   PMID:17326667   PMID:17336988   PMID:17720994   PMID:18288929   PMID:18360691   PMID:18377911   PMID:18559657   PMID:19056867   PMID:19362542   PMID:19382209  
PMID:19414061   PMID:19717566   PMID:19816508   PMID:19946888   PMID:20005821   PMID:20456011   PMID:20458337   PMID:20551380   PMID:21593558   PMID:21630459   PMID:21700703   PMID:21784977  
PMID:22206666   PMID:22516433   PMID:22637583   PMID:22674573   PMID:22871113   PMID:23103361   PMID:23142051   PMID:23376485   PMID:23533145   PMID:23620513   PMID:23640054   PMID:23658023  
PMID:23676495   PMID:23741427   PMID:23845000   PMID:24154541   PMID:24259049   PMID:24328732   PMID:24345162   PMID:24412220   PMID:24446231   PMID:24769233   PMID:24814386   PMID:25015123  
PMID:25122793   PMID:25207746   PMID:25778834   PMID:26397958   PMID:26545012   PMID:26782580   PMID:27044754   PMID:27068509   PMID:27277003   PMID:27477018   PMID:27559042   PMID:27683909  
PMID:28111074   PMID:28164773   PMID:28356228   PMID:29336888   PMID:30303984   PMID:30958617   PMID:31432127   PMID:33564035   PMID:33575839   PMID:33932558   PMID:34575848   PMID:36104381  
PMID:37081644   PMID:37658943   PMID:38393618  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
GRCr8188,481,889 - 88,485,816 (-)NCBIGRCr8
mRatBN7.2179,353,924 - 79,357,852 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl179,353,916 - 79,357,932 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx184,748,825 - 84,752,747 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0193,300,176 - 93,304,099 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0186,503,931 - 86,507,854 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0180,612,894 - 80,616,820 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl180,612,895 - 80,617,057 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0181,878,372 - 81,882,298 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4179,003,634 - 79,006,387 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1179,081,854 - 79,083,684 (-)NCBI
Celera173,813,122 - 73,817,046 (-)NCBICelera
Cytogenetic Map1q21NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh381944,905,796 - 44,909,393 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1944,905,791 - 44,909,393 (+)EnsemblGRCh38hg38GRCh38
GRCh371945,409,053 - 45,412,650 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 361950,100,879 - 50,104,490 (+)NCBINCBI36Build 36hg18NCBI36
Build 341950,100,878 - 50,104,489NCBI
Celera1942,213,361 - 42,216,972 (+)NCBICelera
Cytogenetic Map19q13.32NCBI
HuRef1941,839,825 - 41,843,436 (+)NCBIHuRef
CHM1_11945,411,793 - 45,415,404 (+)NCBICHM1_1
T2T-CHM13v2.01947,730,492 - 47,734,089 (+)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm39719,430,169 - 19,434,326 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl719,430,034 - 19,433,113 (-)EnsemblGRCm39 Ensembl
GRCm38719,696,244 - 19,701,310 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl719,696,109 - 19,699,188 (-)EnsemblGRCm38mm10GRCm38
MGSCv37720,281,593 - 20,284,515 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36718,854,794 - 18,857,554 (-)NCBIMGSCv36mm8
Celera717,102,329 - 17,105,251 (-)NCBICelera
Cytogenetic Map7A3NCBI
cM Map79.94NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_0049555551,999,711 - 2,001,888 (+)EnsemblChiLan1.0
ChiLan1.0NW_0049555551,998,170 - 2,002,003 (+)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan1-v22051,065,455 - 51,069,038 (+)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan11952,937,264 - 52,940,847 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01941,853,669 - 41,857,252 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11950,459,906 - 50,463,490 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl1950,459,906 - 50,463,490 (+)Ensemblpanpan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.11110,525,717 - 110,528,534 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1110,525,722 - 110,528,440 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1110,006,660 - 110,009,463 (-)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01111,055,483 - 111,058,288 (-)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl1111,055,483 - 111,058,228 (-)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.11110,730,139 - 110,732,942 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01110,365,616 - 110,368,413 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01111,234,400 - 111,237,204 (-)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_02440934917,165,062 - 17,169,462 (+)NCBIHiC_Itri_2
SpeTri2.0NW_0049367061,512,438 - 1,516,805 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl651,372,292 - 51,375,330 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.1651,373,113 - 51,375,333 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2647,269,973 - 47,272,195 (+)NCBISscrofa10.2Sscrofa10.2susScr3
Pig Cytomap6q1.2-q2.12NCBI
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.1638,377,154 - 38,381,219 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl638,376,887 - 38,381,438 (+)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366607317,947,315 - 17,951,250 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla 1.0NW_0046249071,752,322 - 1,755,308 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Apoe
48 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:101
Count of miRNA genes:77
Interacting mature miRNAs:84
Prediction methods:Microtar, Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1554320Bmd1Bone mineral density QTL 112.20.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)150910886060548Rat
631688Hcas2Hepatocarcinoma susceptibility QTL 230.0001liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)15925874115540829Rat
2313062Bmd73Bone mineral density QTL 733.90.0001tibia mineral mass (VT:1000283)compact volumetric bone mineral density (CMO:0001730)11148131282174945Rat
2313065Bss67Bone structure and strength QTL 673.10.0001tibia area (VT:1000281)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
2313069Bss68Bone structure and strength QTL 682.90.0001tibia size trait (VT:0100001)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
2313075Bss66Bone structure and strength QTL 663.40.0001tibia length (VT:0004357)tibia length (CMO:0000450)11148131282174945Rat
2313077Bss69Bone structure and strength QTL 693.50.0001tibia strength trait (VT:1000284)bone polar moment of inertia (CMO:0001558)11148131282174945Rat
2313092Bmd72Bone mineral density QTL 722.50.0001tibia mineral mass (VT:1000283)total volumetric bone mineral density (CMO:0001728)11148131282174945Rat
2313097Bss70Bone structure and strength QTL 703.50.0001tibia strength trait (VT:1000284)tibia total energy absorbed before break (CMO:0001736)11148131282174945Rat
631495Bp96Blood pressure QTL 964.52arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)122340647102268831Rat
1358359Sradr1Stress Responsive Adrenal Weight QTL 14.74adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)130882023123479925Rat
70225Bp58Blood pressure QTL 583.3arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)132356093162846471Rat
1300172Bp172Blood pressure QTL 1723.56arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)13273727390665040Rat
10059597Bp377Blood pressure QTL 3773.420.025arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)132737458199368955Rat
8552900Pigfal1Plasma insulin-like growth factor 1 level QTL 17.4blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)13483685879836858Rat
8552948Pigfal11Plasma insulin-like growth factor 1 level QTL 114.7blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)13483685879836858Rat
9589820Insglur3Insulin/glucose ratio QTL 310.750.001blood insulin amount (VT:0001560)calculated plasma insulin level (CMO:0002170)13483685879836858Rat
2313051Bss57Bone structure and strength QTL 573.70.0001tibia strength trait (VT:1000284)bone polar moment of inertia (CMO:0001558)143284731118944897Rat
2313059Bss55Bone structure and strength QTL 553.20.0001tibia size trait (VT:0100001)tibia midshaft cross-sectional area (CMO:0001717)143284731118944897Rat
2313072Bss53Bone structure and strength QTL 534.30.0001tibia length (VT:0004357)tibia length (CMO:0000450)143284731118944897Rat
2313078Bss54Bone structure and strength QTL 543.50.0001tibia area (VT:1000281)tibia midshaft cross-sectional area (CMO:0001717)143284731118944897Rat
2313094Bss58Bone structure and strength QTL 583.70.0001tibia strength trait (VT:1000284)tibia total energy absorbed before break (CMO:0001736)143284731118944897Rat
2313098Bmd70Bone mineral density QTL 703.60.0001tibia mineral mass (VT:1000283)compact volumetric bone mineral density (CMO:0001730)143284731118944897Rat
2313099Bss56Bone structure and strength QTL 562.40.0001tibia size trait (VT:0100001)tibia midshaft endosteal cross-sectional area (CMO:0001716)143284731118944897Rat
2302059Pia36Pristane induced arthritis QTL 363.80.001blood immunoglobulin amount (VT:0002460)serum immunoglobulin G1 level (CMO:0002115)14333300288333002Rat
2313402Anxrr24Anxiety related response QTL 24aggression-related behavior trait (VT:0015014)tameness/aggressiveness composite score (CMO:0002136)148963584144267916Rat
4889962Bss94Bone structure and strength QTL 943.8tibia area (VT:1000281)tibia-fibula cortical bone endosteal cross-sectional area (CMO:0001722)14936146582174945Rat
1578649Bmd8Bone mineral density QTL 84.9femur mineral mass (VT:0010011)trabecular volumetric bone mineral density (CMO:0001729)14939317294393172Rat
1578654Bss10Bone structure and strength QTL 104femur morphology trait (VT:0000559)femoral neck cortical cross-sectional area (CMO:0001702)149393172159356837Rat
634314Niddm44Non-insulin dependent diabetes mellitus QTL 44blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)149393289199050459Rat
6903308Scl36Serum cholesterol QTL 3620.0125blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)15386304190532583Rat
4889919Bss86Bone structure and strength QTL 864.1tibia area (VT:1000281)tibia midshaft total cross-sectional area (CMO:0001715)15389511782174945Rat
4889929Bss87Bone structure and strength QTL 876.7tibia area (VT:1000281)tibia-fibula cortical bone endosteal cross-sectional area (CMO:0001722)15389511782174945Rat
61342Bp27Blood pressure QTL 273.40.0006arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)15673266898773277Rat
2300164Bmd44Bone mineral density QTL 445.40.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)156949932101949932Rat
2298545Neuinf8Neuroinflammation QTL 84.6nervous system integrity trait (VT:0010566)spinal cord beta-2 microglobulin mRNA level (CMO:0002125)157336763151090257Rat
1300121Hrtrt1Heart rate QTL 13.7heart pumping trait (VT:2000009)heart rate (CMO:0000002)165789093115540829Rat
7421628Bp361Blood pressure QTL 3610.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)166023617118608521Rat
631512Scl6Serum cholesterol level QTL 69.6blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)17219768090508767Rat
1358192Ept13Estrogen-induced pituitary tumorigenesis QTL 133.4pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)177494165122494165Rat
10054135Gmadr2Adrenal mass QTL 21.970.0129adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)177857876122857876Rat
1549903Bp267Blood pressure QTL 267arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)177876254106047988Rat
61344Bp29Blood pressure QTL 297.5arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)178350581123350581Rat
7411712Strs4Sensitivity to stroke QTL 48.7cerebrum integrity trait (VT:0010549)percentage of study population developing cerebrovascular lesions during a period of time (CMO:0000932)178430536123430536Rat
61433Cia2Collagen induced arthritis QTL 25joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)17843075491209302Rat
1582234Gluco18Glucose level QTL 183.40.0003blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)178479925123479925Rat

Markers in Region
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2179,353,737 - 79,353,972 (+)MAPPERmRatBN7.2
Rnor_6.0180,612,708 - 80,612,942NCBIRnor6.0
Rnor_5.0181,878,186 - 81,878,420UniSTSRnor5.0
RGSC_v3.4179,003,448 - 79,003,682UniSTSRGSC3.4
Celera173,812,936 - 73,813,170UniSTS
Cytogenetic Map1q21UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2179,353,732 - 79,353,885 (+)MAPPERmRatBN7.2
Rnor_6.0180,612,703 - 80,612,855NCBIRnor6.0
Rnor_5.0181,878,181 - 81,878,333UniSTSRnor5.0
RGSC_v3.4179,003,443 - 79,003,595UniSTSRGSC3.4
Celera173,812,931 - 73,813,083UniSTS
Cytogenetic Map1q21UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2179,354,728 - 79,355,192 (+)MAPPERmRatBN7.2
Rnor_6.0180,613,699 - 80,614,162NCBIRnor6.0
Rnor_5.0181,879,177 - 81,879,640UniSTSRnor5.0
Celera173,813,927 - 73,814,390UniSTS
Cytogenetic Map1q21UniSTS

Genetic Models
This gene Apoe is modified in the following models/strains:


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High 34 29 29 28 10
Medium 3 43 23 12 19 12 8 11 46 35 31 11 8
Below cutoff